膀胱过度活动症治疗市场策略、顶尖企业、增长机会、2028 年分析及预测

  • Report Code : TIPRE00004082
  • Category : Pharmaceuticals
  • Status : Published
  • No. of Pages : 209
Buy Now

Overactive Bladder Treatment Market Size, Trends, Analysis 2028

Buy Now

 

膀胱过度活动症治疗市场预计将从 2021 年的 42.9593 亿美元增长到 2028 年的 53.3392 亿美元;预计 2022 年至 2028 年的复合年增长率为 3.1%。

膀胱过度活动症 (OAB) 是指频繁且突然的尿意,可能难以控制。OAB 可能是由于腹部创伤、感染、神经损伤和某些药物引起的。OAB 在 65 岁及以上的人群中很常见。女性在 45 岁后可能会患上 OAB。治疗包括改变某些行为、药物和神经刺激。

膀胱过度活动症治疗市场细分为药物治疗、疾病类型和地域。按地域划分,市场大致分为北美、欧洲、亚太地区、中东和非洲以及南美和中美洲。膀胱过度活动症治疗市场报告提供了对市场的见解和深入分析,强调了市场趋势、市场动态和全球领先市场参与者的竞争分析等参数。

 

定制研究以满足您的需求

我们可以优化和定制标准产品无法满足的分析和范围。这种灵活性将帮助您获得业务规划和决策所需的准确信息。

膀胱过度活动症治疗市场:

Overactive Bladder Treatment Market: Strategic Insights

Overactive Bladder Treatment Market
  • CAGR
    CAGR (2021 - 2028)
    3.1%
  • Market Size 2021
    US$ 4.3 Billion
  • Market Size 2028
    US$ 5.33 Billion

Market Dynamics

GROWTH DRIVERS
  • XXXXXXX
  • XXXXXXX
  • XXXXXXX
FUTURE TRENDS
  • XXXXXXX
  • XXXXXXX
  • XXXXXXX
OPPORTUNITIES
  • XXXXXXX
  • XXXXXXX
  • XXXXXXX

Key Players

  • Alembic Pharmaceuticals Limited
  • Astellas Pharma Inc
  • Pfizer Inc
  • AbbVie Inc
  • Teva Pharmaceutical Industries Ltd
  • Endo Pharmaceuticals Inc
  • Hisamitsu Pharmaceutical Co Inc
  • Medtronic Plc
  • Colorado Urology Associates PLLC

Regional Overview

Regional And Country Scope
  • 北美(美国、加拿大、墨西哥)
  • 欧洲(英国、德国、法国、俄罗斯、意大利、欧洲其他地区)
  • 亚太地区(中国、印度、日本、澳大利亚、亚太地区其他地区)
  • 南美洲和中美洲(巴西、阿根廷、南美洲和中美洲其他地区)
  • 中东和非洲(南非、沙特阿拉伯、阿联酋、中东和非洲其他地区)

Market Segmentation

Segment 1药物治疗(抗胆碱药物、米拉贝隆、肉毒杆菌、神经刺激和膀胱内灌注)
    Segment2疾病类型(特发性膀胱过度活动症和神经源性膀胱)

      膀胱过度活动症治疗市场
      • Overactive Bladder Treatment Market
        复合年增长率(2021 - 2028 年)
        3.1%
      • 2021 年市场规模
        43 亿美元
      • 2028 年市场规模
        53.3 亿美元

      市场动态

      增长动力
      • 財政部
      • 財政部
      • 財政部
      未来的趋势
      • 財政部
      • 財政部
      • 財政部
      机会
      • 財政部
      • 財政部
      • 財政部

      关键人物;主力;重要一员

      •  
      • Alembic 制药有限公司
      • 安斯泰来制药公司
      • 辉瑞公司
      • 艾伯维公司
      • 梯瓦制药工业有限公司
      • Endo 制药公司
      • 久光制药株式会社
      • 美敦力公司
      • 科罗拉多泌尿科协会

      区域概况

      Overactive Bladder Treatment Market
      • 北美
      • 欧洲
      • 亚太
      • 南美洲和中美洲
      • 中东和非洲

      市场细分

      Overactive Bladder Treatment Market药物治疗
      • 抗胆碱能药物
      • 米拉贝隆
      • 肉毒杆菌
      • 神经刺激
      • 膀胱灌注
      Overactive Bladder Treatment Market疾病类型
      • 特发性膀胱过度活动症和神经源性膀胱
      • 示例 PDF 通过定性和定量分析展示了内容结构和信息的性质。

       

      市场洞察

       

      根据美国国家尿失禁协会的数据,2018 年,全球约有 2 亿人患有尿失禁。压力性尿失禁和急迫性尿失禁是影响女性的两种常见尿失禁类型,其中后者也称为膀胱过度活动症。同样,美国内科医师学会和美国传染病学会的一组研究人员在 2020 年进行的一项研究表明,尿路感染 (UTI)是美国每年约 600 万人次就诊的原因。在加拿大,每年约有 500,000 人次就诊是为了进行 UTI 咨询。UTI 是该国门诊就诊和急诊就诊的第八大和第五大常见原因。因此,尿失禁患病率的增加和尿路感染发病率的上升正在推动膀胱过度活动症治疗市场的发展。

       

      以下是一些新产品发布和批准的示例:

       

      • 2022 年 2 月,Alembic Pharmaceuticals 获得美国卫生监管机构批准其仿制药富马酸非索罗定缓释片,用于治疗成人膀胱过度活动症,症状包括尿失禁、尿急和尿频。美国食品药品监督管理局 (USFDA) 批准的富马酸非索罗定缓释片简化新药申请 (ANDA) 的规格为 4 毫克和 8 毫克。
      • 2022 年 4 月,全球医疗技术公司 Axonics, Inc. 宣布在美国全面推出 Axonics F15,该公司开发和商业化用于治疗膀胱和肠道功能障碍的新产品。新开发的长寿命、完全免充电的骶神经调节 (SNM) 系统于 3 月获得 FDA 批准。Axonics 免充电系统对于患有膀胱和肠道功能障碍的患者来说是一项可喜的进步。
      • 2021年3月,安斯泰来制药的Myrbetriq(用于治疗3岁及以上(体重35公斤以上)儿科患者的神经源性逼尿肌过度活动(NDO))和Myrbetriq颗粒(用于治疗3岁及以上儿科患者的NDO)获得美国食品药品监督管理局(FDA)批准。

      市场参与者对此类产品的开发正在推动膀胱过度活动症治疗市场的发展。

       

      类型洞察

      根据药物治疗,膀胱过度活动症治疗市场细分为米拉贝隆、肉毒杆菌毒素、神经刺激、抗胆碱能药物和膀胱内灌注。米拉贝隆部分在 2021 年占据了最大的市场份额,预计在预测期内将实现最高的复合年增长率。米拉贝隆可单独使用或与索利那新一起用于治疗成人膀胱过度活动症。它用​​于治疗三岁或以上儿童的神经源性逼尿肌过度活动(由大脑、脊髓或神经问题引起的膀胱控制状况)。米拉贝隆属于称为 β-3 肾上腺素能激动剂的一类药物。它可以放松膀胱肌肉,防止尿急、尿频或尿失禁。米拉贝隆有缓释(长效)片剂和缓释混悬液两种形式,可口服。 2022 年 10 月,Zydus Pharmaceuticals Inc. 获得美国食品药品监督管理局 (FDA) 批准销售 Mirabegron 缓释片 USP 25 毫克和 50 毫克。预计在预测期内,对这种疗法的需求不断增长将推动膀胱过度活动症治疗市场的增长。

       

      服务洞察

       

      根据药物治疗,膀胱过度活动症治疗市场细分为米拉贝隆、肉毒杆菌毒素、神经刺激、抗胆碱能药物和膀胱内灌注。预计神经刺激部分将在预测期内实现最高的复合年增长率。膀胱的神经控制很复杂,取决于不同的脊髓、中枢和周围神经及其多种反射通路。神经控制在人体的不同部位进行,因此针对不同的神经。其中一些目标神经直接参与下尿路感觉运动控制,如骶神经或阴部神经,而另一些则更间接地参与。电刺激用于激活这些神经来控制膀胱。

      伙伴关系和合作是全球膀胱过度活动症治疗市场参与者广泛采用的策略。以下列出了一些近期的关键市场发展:

      • 2021 年 4 月,美敦力公司宣布获得美国食品药品监督管理局 (FDA) 批准进行一项临床试验豁免 (IDE) 试验,以评估其内部开发的可植入胫骨神经调节 (TNM) 装置,这是一种旨在缓解膀胱失禁症状的治疗方法。
      • 2020 年 7 月,久光制药株式会社宣布 OABLOK PATCH 获准在泰国生产和销售。该产品是一种全身透皮制剂,采用久光透皮给药系统 (TDDS) 技术开发,用于治疗伴有尿急和尿频等症状的膀胱过度活动症。
      • 2019年7月,梯瓦制药有限公司 (Teva Pharmaceuticals Ltd.) 推出了琥珀酸索利那新片,这是一种毒蕈碱拮抗剂,用于治疗伴有尿失禁和尿频增加症状的膀胱过度活动症。

      COVID-19 疫情为膀胱过度活动症治疗市场的参与者带来了一些有利的前景。美国是北美受疫情影响最严重的国家。该感染严重影响了该国的老年人口,引发了各种并发症,并导致大量人口死亡。例如,截至 2022 年 5 月 16 日,美国报告了 84,230,829 例 COVID 病例,其中 1,026,670 例死亡。因此,需要进行膀胱过度活动症治疗和适当的护理,以预防慢性感染和健康状况。

      新冠疫情爆发后,膀胱过度活动症(OAB)的发病率有所上升。美国泌尿协会的一项研究表明,感染新冠的患者出现新的或恶化的膀胱过度活动症症状的风险增加。此外,约三分之一的新冠患者在感染两个月后进行的国际失禁问卷膀胱过度活动症模块咨询(ICIQ-OAB)中报告临床症状显著增加。在这三分之一的患者中,约五分之一的患者报告他们出现了新的OAB症状。新冠疫情导致的OAB患病率上升对疫情期间膀胱过度活动症治疗的需求产生了积极影响。

       

      膀胱过度活动症治疗市场报告范围

      报告属性细节
      2021 年市场规模43亿美元
      2028 年市场规模53.3亿美元
      全球复合年增长率(2021 - 2028)3.1%
      历史数据2019-2020
      预测期2022-2028
      涵盖的领域通过药物治疗
      • 抗胆碱能药物
      • 米拉贝隆
      • 肉毒杆菌
      • 神经刺激
      • 膀胱灌注
      按疾病类型
      • 特发性膀胱过度活动症和神经源性膀胱
      覆盖地区和国家北美
      • 我们
      • 加拿大
      • 墨西哥
      欧洲
      • 英国
      • 德国
      • 法国
      • 俄罗斯
      • 意大利
      • 欧洲其他地区
      亚太
      • 中国
      • 印度
      • 日本
      • 澳大利亚
      • 亚太其他地区
      南美洲和中美洲
      • 巴西
      • 阿根廷
      • 南美洲和中美洲其他地区
      中东和非洲
      • 南非
      • 沙特阿拉伯
      • 阿联酋
      • 中东和非洲其他地区
      市场领导者和主要公司简介
      •  
      • Alembic 制药有限公司
      • 安斯泰来制药公司
      • 辉瑞公司
      • 艾伯维公司
      • 梯瓦制药工业有限公司
      • Endo 制药公司
      • 久光制药株式会社
      • 美敦力公司
      • 科罗拉多泌尿科协会
      • 示例 PDF 通过定性和定量分析展示了内容结构和信息的性质。

       

      膀胱过度活动症治疗——市场细分

      全球膀胱过度活动症治疗市场根据药物疗法、疾病类型和地理位置进行分析。根据药物疗法,膀胱过度活动症治疗市场分为米拉贝隆、肉毒杆菌毒素、神经刺激、抗胆碱能药物和膀胱内灌注。根据疾病类型,市场分为特发性膀胱过度活动症和神经源性膀胱。从地理位置上看,膀胱过度活动症治疗市场分为北美、欧洲、亚太地区、中东和非洲以及南美和中美洲。  

       

      公司简介

      • Alembic 制药有限公司
      • 安斯泰来制药公司
      • 艾伯维公司
      • 梯瓦制药工业有限公司
      • 远藤制药公司
      • 久光制药株式会社
      • 美敦力公司
      • 科罗拉多泌尿科协会
      • Axonics 调制技术有限公司
      • 辉瑞公司

      Overactive Bladder Treatment Market Report Scope

      Report Attribute Details
      Market size in US$ 4.3 Billion
      Market Size by US$ 5.33 Billion
      Global CAGR 3.1%
      Historical Data 2019-2020
      Forecast period 2022-2028
      Segments Covered By 药物治疗(抗胆碱药物、米拉贝隆、肉毒杆菌、神经刺激和膀胱内灌注)
      By 疾病类型(特发性膀胱过度活动症和神经源性膀胱)
      Regions and Countries Covered 北美(美国、加拿大、墨西哥)
      • 北美(美国、加拿大、墨西哥)
      欧洲(英国、德国、法国、俄罗斯、意大利、欧洲其他地区)
      • 欧洲(英国、德国、法国、俄罗斯、意大利、欧洲其他地区)
      亚太地区(中国、印度、日本、澳大利亚、亚太地区其他地区)
      • 亚太地区(中国、印度、日本、澳大利亚、亚太地区其他地区)
      南美洲和中美洲(巴西、阿根廷、南美洲和中美洲其他地区)
      • 南美洲和中美洲(巴西、阿根廷、南美洲和中美洲其他地区)
      中东和非洲(南非、沙特阿拉伯、阿联酋、中东和非洲其他地区)
      • 中东和非洲(南非、沙特阿拉伯、阿联酋、中东和非洲其他地区)
      Market leaders and key company profiles
    • Alembic Pharmaceuticals Limited
    • Astellas Pharma Inc
    • Pfizer Inc
    • AbbVie Inc
    • Teva Pharmaceutical Industries Ltd
    • Endo Pharmaceuticals Inc
    • Hisamitsu Pharmaceutical Co Inc
    • Medtronic Plc
    • Colorado Urology Associates PLLC
    • Report Coverage
      Report Coverage

      Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

      Segment Covered
      Segment Covered

      This text is related
      to segments covered.

      Regional Scope
      Regional Scope

      North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

      Country Scope
      Country Scope

      This text is related
      to country scope.

      Frequently Asked Questions


      What are the driving factors for the global overactive bladder treatment market across the world?

      The factors that are driving the growth of the overactive bladder treatment market are urinary tract infections (UTI) which lead to increased activity in the bladder wall muscles, causing symptoms like an overactive bladder. The bacteria causing UTIs reside in the lining of urothelial cells, and they attack the host body when their innate immunity is low. Individuals with recurrent UTIs are found to have voiding dysfunction and detrusor overactivity, and these functional abnormalities may further damage the integrity of the urothelial barrier. The increasing prevalence of UTIs, coupled with the association of UTIs with overactive bladder, is one of the prominent factors contributing to the overactive bladder treatment market growth.

      What is the market CAGR value of the overactive bladder treatment market during the forecast period?

      The CAGR value of the overactive bladder treatment market during the forecasted period of 2022-2028 is 3.1%.

      What is the estimated overactive bladder treatment market size in 2021?

      The overactive bladder treatment market is estimated to be valued at US$ 4,295.93 million in 2021.

      What are the growth estimates for the overactive bladder treatment market till 2028?

      The overactive bladder treatment market is expected to be valued at US$ 5,333.92 million in 2028.

      Who are the major players in the overactive bladder treatment market across the globe?

      The overactive bladder treatment market majorly consists of the players, such as Alembic Pharmaceuticals Limited, Astellas Pharma Inc; Pfizer Inc; AbbVie Inc; Teva Pharmaceutical Industries Ltd; Endo Pharmaceuticals Inc; Hisamitsu Pharmaceutical Co., Inc; Medtronic Plc; Colorado Urology Associates, PLLC; Axonics Modulation Technologies, Inc.

      Which segment by pharmacotherapy led the overactive bladder treatment market?

      The mirabegron segment held the largest share of the market in 2021. However, neurostimulation is expected to grow at the highest CAGR during the forecast period.

      Which region is projected to be the fastest-growing region in the global overactive bladder treatment market?

      The Asia Pacific is expected to be the fastest-growing region in the overactive bladder treatment market over the forecast period due to the rising geriatric population, increasing urinary incontinence cases, and a surge in product launches.

      What are overactive bladder treatments?

      The sudden need to urinate causes a problem with bladder dysfunction. An overactive bladder may affect how often you pee and your urgency. Causes include abdominal trauma, infection, nerve damage, medications, and certain fluids. Treatment includes changing certain behaviors, medications, and nerve stimulation. Overactive bladder is common in people aged 65 and older. Women may have OAB at a younger age, usually around 45.

      The List of Companies -Overactive Bladder Treatment Market

      1. Alembic Pharmaceuticals Limited
      2. Astellas Pharma Inc
      3. Pfizer Inc
      4. AbbVie Inc
      5. Teva Pharmaceutical Industries Ltd
      6. Endo Pharmaceuticals Inc.
      7. Hisamitsu Pharmaceutical Co.,Inc
      8. Medtronic Plc
      9. Colorado Urology Associates, PLLC
      10. Axonics Modulation Technologies, Inc

      The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

      1. Data Collection and Secondary Research:

      As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

      Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

      1. Primary Research:

      The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

      For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

      A typical research interview fulfils the following functions:

      • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
      • Validates and strengthens in-house secondary research findings
      • Develops the analysis team’s expertise and market understanding

      Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

      • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
      • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

      Below is the breakup of our primary respondents by company, designation, and region:

      Research Methodology

      Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

      1. Data Analysis:

      Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

      • Macro-Economic Factor Analysis:

      We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

      • Country Level Data:

      Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

      • Company Profile:

      The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

      • Developing Base Number:

      Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

      1. Data Triangulation and Final Review:

      The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

      We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

      We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

      Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

      Trends and growth analysis reports related to Pharmaceuticals : READ MORE..